oral+semaglutide+approval Semaglutide, the First Oral GLP-1 for Type 2 Diabetes Oral Obesity Drugs Edge Closer

Throughout 2024 and 2025, Lilly and Novo waged aggressive litigation campaigns to shut down compounding pharmacies selling knockoff versions of their drugs for $130-200 per month, arguing the copycat products posed safety risks and violated FDA rules

PMID: 46 HouSLiCWangYSunJGuoYNingXet al

Should Every Patient See a Dietitian

Note: Location counts are approximate

Diarrhoea is reported in around 30% of users across the STEP trials

However, we all know that too much cholesterol in the blood can lead to some serious health issues, including the formation of plaque in the arteries and even reduced oxygen flow to the heart